INTRODUCTION {#s1}
============

In the preceding paper ([@AGR135C5]), we have demonstrated the ability of 3 tryptophan (Trp) metabolites of the kynurenine pathway, namely 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA) and kynurenic acid (KA), to inhibit the rat liver mitochondrial low K~m~ aldehyde dehydrogenase (ALDH) activity after administration, to elevate blood acetaldehyde concentration following acute ethanol administration and to induce aversion to alcohol in an experimental rat model. On the basis of these findings, we suggested that the above metabolites may form the basis of a new alcohol aversion therapy. A US patent (to AA-BB) is expected shortly for the use of 3-HK and 3-HAA and suitable derivatives thereof in the treatment of alcoholism by aversion. However, the clinical development of these metabolites and their derivatives requires further studies. A more immediate and potentially superior alternative approach is to use their parent compound Trp. However, Trp acutely administered alone may not produce sufficient sustainable ALDH-inhibitory amounts of the above kynurenine metabolites, but can do so if given under suitable conditions, namely metabolic blockade at the kynureninase step of the hepatic kynurenine pathway. As well as via this major pathway of Trp degradation, Trp is also metabolized by three minor pathways, the serotonin-biosynthetic, the decarboxylation or tryptamine and the transamination, pathways (Fig. [1](#AGR135F1){ref-type="fig"}) (for reviews, see [@AGR135C2], [@AGR135C3]). It is important to emphasize here a number of aspects of the kynurenine pathway (for review, see [@AGR135C8]) in the context of the present work, namely that: (a) the most rate-limiting enzyme is Trp 2,3-dioxygenase, with the next rate-limiting enzyme being kynureninase and that kynurenine hydroxylase is not rate-limiting under normal conditions. (b) Kynurenine aminotransferase catalyses minor reactions under normal conditions, but these could become quantitatively more significant under conditions of loading with Trp or kynurenine ([@AGR135C8]). (c) The main kynureninase reaction in the liver is that using 3-HK and not kynurenine as substrate ([@AGR135C8]) (although in the *in vitro* assays of this enzyme, kynurenine is usually used). (d) Blockade of the kynureninase reaction will inhibit the formation of 3-HAA, which, in turn, will limit quinolinic acid formation. (e) Kynureninase blockade in the presence of Trp loading could also lead to accumulation of KA. (f) This latter metabolite is the physiological antagonist, whereas quinolinic acid is the physiological agonist, of the *N*-methyl-*D*-aspartate (NMDA) type of glutamate receptors ([@AGR135C41]) and, although entry of KA into the brain is normally relatively limited, that of kynurenine is not ([@AGR135C15]). Quinolinic acid entry into the brain has also been suggested to be equally limited ([@AGR135C15]), although other evidence suggests that peripheral blood plays a significant role in its cerebral uptake ([@AGR135C19]). It is therefore possible that Trp loading combined with liver kynureninase inhibition could afford dual neuronal protection against NMDA receptor activity. (g) With Trp loading, formation of serotonin in the brain is also expected to be enhanced. Fig. 1.Schematic representation of the tryptophan degradative pathways. These are: 1. the kynurenine pathway; 2. the serotonin pathway; 3. the decarboxylation or tryptamine pathway; 4. the aminotransferase pathway. Metabolites in bold letters are inhibitors of ALDH activity.

As progress in developing more effective drug therapies is hampered by the multifactorial nature of the alcohol dependence process and the limited capacity of current and potential drugs to influence only one aspect of this process, it has been suggested ([@AGR135C26]; [@AGR135C20]) that progress is more likely to be achieved using combination therapy. Our proposed strategy, based on the above principles, appears to satisfy the requirements for a potentially successful alcoholism therapy, one acting simultaneously on alcohol consumption through aversion, on anxiety and depression, and possibly also reward, through provision of serotonin and on hyperexcitability through decreased NMDA receptor function.

In the present paper, we provide evidence for proof of mechanism (ALDH inhibition) and of principle (induction of aversion to alcohol) by the combined administration of Trp with the kynureninase inhibitor benserazide (BSZ). This latter drug is best known for its inhibition of aromatic *L*-amino acid decarboxylase (ALAAD) activity during therapy of Parkinson\'s disease when co-administered with the dopamine precursor 3,4-dihydroxyphenylalanine (*L*-dopa). The other ALAAD inhibitor carbidopa (also used with *L*-dopa) is an even-stronger kynureninase inhibitor ([@AGR135C9]; [@AGR135C7]) and was therefore also studied in the present work.

MATERIALS AND METHODS {#s2}
=====================

Chemicals and other materials {#s2a}
-----------------------------

BSZ \[DL-serine 2(2,3,4-trihydroxybenzyl) hydrazine hydrochloride\] and carbidopa \[2(S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid\] were purchased from the Sigma-Aldrich Co Ltd. (Fancy Road, Poole, Dorset, UK). All other chemicals and materials were purchased from this and the other sources listed in the preceding paper ([@AGR135C5]).

Animals and treatments {#s2b}
----------------------

Adult normal male Wistar rats weighing between 150 and 170 g at the start of experiments were purchased from accredited animal suppliers and were acclimatized to our standard UK Home Office-approved housing conditions (21 ± 2°C, relative humidity of 55 ± 10% and a 12 h/12 h light:dark cycle) for at least one week before experiments. They were housed five per cage, unless stated otherwise, in conventional open-top cages with standard softwood bedding from accredited suppliers, and were allowed free access to standard laboratory RM1 diet and water. Adult male mice of the alcohol-preferring C57BL/6J strain, weighing between 18 and 21 g at the start of experiments, were also studied. This study was performed under the auspices of Cardiff University and approved and licensed (project licence No: PPL 30/2502) by the UK Home Office under the Animal (Scientific Procedures) Act 1986. All compounds were administered intraperitoneally in 0.9% (w/v) NaCl (physiological saline) in single doses as follows: Trp (50 mg/kg); BSZ (100 mg/kg), carbidopa (50 mg/kg). When administered in combinations, BSZ, carbidopa or an equal volume (1 ml/kg) of saline was injected 15 min, 30 min or 1 h before Trp or an equal volume of saline ((2.5 ml/kg). When given repeatedly for up to 7 days, BSZ, carbidopa and Trp were injected in single daily doses either separately or in combinations as above.

Determination of ALDH activity *in vitro* and *in vivo* {#s2c}
-------------------------------------------------------

The mitochondrial low K~m~ ALDH activity was determined *in vitro* by the method of [@AGR135C43] in liver supernatants prepared according to [@AGR135C27], and *in vivo* by measuring the accumulation of acetaldehyde in blood following acute ethanol administration. Both procedures have been described in detail in the preceding paper ([@AGR135C5]). The blood acetaldehyde concentrations reported in the 'Results' section in the present paper have also been corrected for the artifactual formation described in the preceding paper, in which pitfalls in acetaldehyde determination have been addressed in detail.

Alcohol aversion test {#s2d}
---------------------

Aversion to alcohol was assessed using the alcohol aversion model of [@AGR135C17] Briefly, individually housed rats were allowed free access to food and water for 3 days. Trp, BSZ or carbidopa were administered in the above single doses once daily for 4 days, either separately or in combinations wherein BSZ, carbidopa or saline was injected 15 min before Trp or saline. On the evening of the third day, water (but not food) was withdrawn for 18 h, but was then replaced by a 6% (v/v) ethanol solution, 2 h after the injection on the fourth day. Body wt was measured daily and alcohol consumption was monitored hourly for 4 h and levels were expressed cumulatively over this duration in g/kg body wt.

Alcohol consumption and preference in alcohol-preferring C57BL/6J mice {#s2e}
----------------------------------------------------------------------

As in the preceding paper ([@AGR135C5]), no attempt was made to enhance alcohol preference by acclimatizing the mice to increasing ethanol concentrations, as the purpose of our study was to investigate aversion, rather than preference. Accordingly, four groups (*n* = 8 each) of individually housed mice were given free choice between drinking water and a 10% (v/v) ethanol solution for 16 days to establish their drinking patterns. Thereafter, mice were pretreated once daily with a single intraperitoneal injection of BSZ (100 mg/kg body wt) or an equal volume (1 ml/kg) of saline 0.25 h before a similar injection of Trp (50 mg/kg) or an equal volume (2.5 ml/kg) of saline, for 5 days. Body wt and water and ethanol consumption were recorded daily throughout the whole study duration. Determined per kg body wt, daily alcohol consumption was expressed in absolute amounts (g) and as a percentage of total fluid intake (% preference).

Determination of liver kynureninase activity {#s2f}
--------------------------------------------

Liver kynureninase activity was determined by measuring the conversion of kynurenine to anthranilic acid by the method of [@AGR135C10] In preliminary experiments, we found that kynureninase activity was linear over the kynurenine concentration range of 0--1 mM and that anthranilic acid formation from kynurenine (1 mM) was linear over a 90 min period. Subsequent experiments were therefore performed at a 1 mM kynurenine concentration with a 30 min incubation time. A 1 g piece of frozen liver was homogenized in 4 ml of an ice-cold homogenization buffer consisting of 20 mM sodium phosphate, containing 140 mM KCl at pH 7.0 for 1 min using an ultra-Turrax homogenizer. The homogenate was then centrifuged at 20 000*g* for 30 min at 4°C. The supernatant was then decanted quantitatively and the volume adjusted to 4 ml with the homogenization buffer. All tests were performed in duplicates with one blank for each rat liver homogenate. To 100 µl of the ice-cold substrate solution (200 mM Tris--HCl buffer, pH 8.0, 100 µM pyridoxal 5′-phosphate and 1 mM kynurenine), 100 µl of the rat liver homogenate was added in a 5 ml plastic tube. The mixture was incubated in a shaking-water bath for 30 min at 37°C. The reaction was stopped by the addition of 200 µl of 24% (w/v) perchloric acid and incubation was continued for a further 2--3 min. The contents of the tubes were centrifuged at 10 000*g* for 10 min at 4°C, after which the supernatant was decanted carefully into an high-performance liquid-chromatographic (HPLC) autosampler vial. The anthranilic acid produced was separated and quantified both fluorimetrically and by UV as described below for kynurenine metabolites. The protein content of the liver postmitochondrial supernatant was determined by the method of [@AGR135C25] using bovine albumin as standard. Enzyme activity was expressed as nmol of anthranilic acid formed/h per mg of protein.

Assessment of kynureninase activity *in vivo* {#s2g}
---------------------------------------------

This can be made by measuring hepatic concentrations of some kynurenine metabolites. The major effect of kynureninase inhibition is elevation of 3-HK concentration ([@AGR135C10]), leading to a decrease in that of 3-HAA. A secondary effect is a potential increase in xanthurenic acid due to elevation of \[3-HK\]. Hepatic concentrations of the above three and other metabolites were therefore determined in the present experiments, using the HPLC methodology of [@AGR135C4] under the conditions described in the preceding paper ([@AGR135C5]).

Statistical analysis {#s2h}
--------------------

Enzymatic and other biochemical test results were compared with those of control groups by the unpaired *t* test, whereas alcohol consumption results were assessed initially by one-way analysis of variance (ANOVA) and additionally for within-group differences (time factor versus baseline values) by paired *t*-tests, using Sigma Plot (Systat, UK), version 11, with which graphics were prepared. For multiple group comparisons using this programme, the Holm-Sidak test was applied, as it is more powerful than the Tukey or Bonferroni tests and can be used for both pairwise comparisons and those versus a control group. Where the data failed the normality (Shapiro--Wilk) test, Kruskal--Wallis one-way ANOVA on ranks was performed. A two-tailed level of significance (*P*) was set at 0.05.

RESULTS {#s3}
=======

Effects of administration of BSZ or carbidopa alone or in combinations with tryptophan on the rat liver mitochondrial low K~m~ ALDH activity {#s3a}
--------------------------------------------------------------------------------------------------------------------------------------------

The acute effects are depicted in Fig. [2](#AGR135F2){ref-type="fig"}. Neither BSZ alone (Fig. [2](#AGR135F2){ref-type="fig"}a) nor carbidopa alone (Fig. [2](#AGR135F2){ref-type="fig"}b) exerted any significant effects on ALDH activity. Similarly, Trp administered alone or with carbidopa did not influence ALDH activity (Fig. [2](#AGR135F2){ref-type="fig"}b). By contrast, combined administration of Trp plus BSZ caused a remarkable inhibition (Fig. [2](#AGR135F2){ref-type="fig"}a). Thus, ALDH activity was decreased by this combined treatment by 46% at 1 h (*P *= 0.0005). Inhibition then progressed over time, reaching 92% at 3 h and remaining at this level 1 h later. Fig. 2.Time-course of effects of acute administration of tryptophan, BSZ, carbidopa and combinations of tryptophan with BSZ or carbidopa on activity of the rat liver mitochondrial low k~m~ ALDH. Tryptophan (50 mg/kg), BSZ (100 mg/kg) or carbidopa (50 mg/kg) was administered intraperitoneally to rats. BSZ (**a**) or carbidopa (**b**) was also administered 30 min before tryptophan (all in the above doses). ALDH activity was determined before and at hourly intervals for 4 h after these treatments as described in the 'Materials and Methods' section. Values are means ± SEM (bars) for each group of five rats. Values at the different time-intervals were compared statistically (*t*-test) with those at zero time and the significance of the differences is indicated by an asterisk (*P *\< 0.0005). Abbreviations used: BSZ, benserazide; CBD, carbidopa; Trp, tryptophan.

Chronic experiments were also performed in which rats were treated with Trp, BSZ or a combination of the two for 7 days. In data not shown, neither Trp alone nor BSZ alone exerted any significant effect on ALDH activity, whereas the combined treatment caused a 55% inhibition (*P *= 0.0001) Although this could be attributed to an acute effect at 2 h after the final treatment, it suggests that no tolerance develops to the acute inhibition after repeated administration of Trp plus BSZ.

Inhibition of AlDH activity *in vivo* by combined administration of tryptophan and BSZ {#s3b}
--------------------------------------------------------------------------------------

The accumulation of acetaldehyde and ethanol in blood following  acute ethanol administration was studied in rats treated with Trp, BSZ or a combination of the two (Fig. [3](#AGR135F3){ref-type="fig"}). Blood acetaldehyde concentration (Fig. [3](#AGR135F3){ref-type="fig"}a) after pretreatment with BSZ did not differ significantly from that in saline-pretreated controls (*P *\> 0.0980). A non-significant trend towards elevated acetaldehyde concentration after pretreatment with Trp was observed (*P *\> 0.0971). By contrast, combined pretreatment with Trp plus BSZ caused a significant elevation of blood acetaldehyde concentration. The strongest effect was at 1 h after ethanol (145 μM), which was significantly different from all the other three groups (*P *= 0.0287--0.0001). At 2 h, the increase caused by Trp plus BSZ was also significant, compared with those in saline or BSZ-pretreated rats (*P *= 0.0029), but, at 3 h, only the difference from saline-pretreated controls was still significant (*P *= 0.0011). Acetaldehyde concentration in Trp plus BSZ-pretreated rats did not differ significantly from that in Trp-pretreated rats at 2 or 3 h. Fig. 3.Effects of acute administration of BSZ, tryptophan or both on rat blood ethanol and acetaldehyde concentrations. Rats received an intraperitoneal injection of BSZ (100 mg/kg body wt) or an equal volume (1 ml/kg) of saline 1 h before a similar injection of tryptophan (50 mg/kg) or an equal volume (2.5 ml/kg) of saline. One hour after the second injection, a 2 g/kg dose of ethanol (as a 25% v/v solution in saline) was administered. Blood samples were analysed for acetaldehyde (**a**) and ethanol (**b**) as described in the 'Materials and Methods' section. Values are means ± SEM (bars) for each group of five rats. All test groups were compared with the saline-pretreated control group (C) by the *t*-test. The BSZ plus tryptophan group was additionally compared with the other two test groups as described in the relevant text of the 'Results' section. Abbreviations used are as in Fig. [2](#AGR135F2){ref-type="fig"}a.

The increase in blood ethanol concentration following ethanol administration to saline-pretreated controls was not significantly influenced by pretreatment with BSZ, Trp or both (Fig. [3](#AGR135F3){ref-type="fig"}b). Pretreatment with Trp alone showed a slightly lower blood ethanol concentrations at 3 h, though not significant (*P \> *0.1). The ethanol area under the curve (AUC) was similar among the saline-, BSZ- and Trp plus BSZ-pretreated groups (80.35, 80.95 and 81.85 mM, respectively) and slightly higher than that in the Trp-pretreated group (76.9 mM).

Demonstration of aversion to alcohol after administration of tryptophan in combination with BSZ, but not with carbidopa {#s3c}
-----------------------------------------------------------------------------------------------------------------------

In the preceding paper ([@AGR135C5]), we have successfully applied the alcohol aversion model of [@AGR135C17] to demonstrate aversion to alcohol by three kynurenine metabolites and to confirm that by the classical AlDH inhibitor disulfiram. In the present work, we tested the same model for possible aversion by Trp and the two kynureninase inhibitors BSZ and carbidopa either alone or in combination with Trp. As the results in Fig. [4](#AGR135F4){ref-type="fig"} show, no aversion to alcohol was observed after administration of Trp alone. BSZ alone (Fig. [4](#AGR135F4){ref-type="fig"}a) also did not inhibit alcohol consumption, except only at 2 h. This particular effect appears to be a spurious result, as it did not occur earlier nor was it maintained thereafter, and it does not fit in with other results described in this paper. Carbidopa alone (Fig. [4](#AGR135F4){ref-type="fig"}b) caused aversion to alcohol, decreasing alcohol consumption by 30--33% consistently at 2--4 h (*P *= 0.0162--0.0017), in comparison with saline-treated controls. Fig. 4.Inhibition of alcohol consumption by carbidopa alone and by combined treatment with BSZ and tryptophan in a rat alcohol aversion model. Groups of rats received single daily intraperitoneal injections for 4 days of BSZ (100 mg/kg body wt), carbidopa (50 mg/kg) or an equal volume (1 ml/kg) of saline 1 h before a similar injection of tryptophan (50 mg/kg) or an equal volume (2.5 ml/kg) of saline. All other details are as described in the 'Materials and Methods' section. Consumption of the ethanol solution was measured hourly in all groups for 4 h and is expressed in g/kg body wt cumulatively. Values are means ± SEM (bars) for each group of 5--6 rats. Sal (saline) and other abbreviations are as in Fig. [2](#AGR135F2){ref-type="fig"}.

Combined administration of Trp with carbidopa (Fig. [4](#AGR135F4){ref-type="fig"}b), however, reversed the carbidopa-induced aversion. Here, alcohol consumption resembled that of saline-treated controls. By contrast, combined treatment with Trp plus BSZ (Fig. [4](#AGR135F4){ref-type="fig"}a) induced consistent inhibition of alcohol consumption, of 38--44% at 1--4 h (*P *= 0.0127--0.0024), compared with saline-treated controls. Alcohol consumption with this combined treatment also differed significantly from that with the Trp-treated group at all four time-intervals (*P *= 0.0253--0.0030) and from the BSZ-treated group at 1 and 4 h (*P *= 0.0274--0.0106).

Effects of tryptophan, BSZ or both on alcohol consumption and preference by C57 mice {#s3d}
------------------------------------------------------------------------------------

After a 16-day period of provision of free choice between drinking water and a 10% (v/v) ethanol solution, four groups (*n* = 8 each) of male alcohol-preferring C57BL/6J mice were treated with single daily doses of saline, Trp, BSZ or a combination of Trp plus BSZ. Six mice from each group were matched on Day 0 for level of alcohol consumption (in g/kg body wt) and preference (%) adjusted per kg body wt, as shown in Fig. [5](#AGR135F5){ref-type="fig"}. There were no significant differences on any one day between the groups receiving saline, Trp or BSZ, either in absolute ethanol intake (Fig. [5](#AGR135F5){ref-type="fig"}a) or preference (Fig. [5](#AGR135F5){ref-type="fig"}b) (ANOVA\'s, *P *\> 0.1). By contrast, combined administration of Trp + BSZ led to lower levels of alcohol consumption and preference. Alcohol intake (g/kg) in this combined group differed significantly only on Day 5 from that in the BSZ- and Trp-treated groups (*P *= 0.05--0.034), whereas alcohol preference (%) differed significantly from that in the saline group on Days 1and 3 (*P *= 0.039--0.015), the Trp group on Days 1, 3 and 5 (*P *= 0.044--0.003) and the BSZ group on Days 1, 3 and 5 (*P *= 0.05--0.009). From these data and the graphs, it is clear that, whereas the three single groups exhibited a cyclical alcohol consummatory behaviour, with a high and a lower intake on alternate days, the combined Trp + BSZ group consistently decreased its alcohol intake continuously with time. Accordingly, because of this cyclical behaviour of the single treatment groups, the absence of significant differences between the Trp + BSZ group and the other three was apparent only on days on which mice of these latter groups decreased their alcohol intake. Fig. 5.Effects of repeated administration of BSZ, tryptophan or both on alcohol consumption and preference in male alcohol-preferring C57BL/6J mice. Experimental details are as described in the 'Materials and Methods' section. Alcohol consumption was monitored daily and is expressed (per kg body wt) for each group from day zero (before the injections) onwards, both in g amounts (**a**) and as a preference % (**b**). Values are means ± SEM (bars) for each group of six mice. For abbreviations, see Fig. [4](#AGR135F4){ref-type="fig"}. For statistical comparisons, see the relevant text in the 'Results' section.

Inhibition of liver kynureninase activity by BSZ and carbidopa and the differential effect of combined treatment with tryptophan {#s3e}
--------------------------------------------------------------------------------------------------------------------------------

The two most potent inhibitors of kynureninase activity *in vitro* are carbidopa and BSZ, with the former being a stronger inhibitor ([@AGR135C9]; [@AGR135C7]). This was partially confirmed in the present work. As shown in Table [1](#AGR135TB1){ref-type="table"}, kynureninase inhibition was similar between BSZ and carbidopa at drug concentrations of 10 μM (17--22%), 25 μM (25--28%) and 100 μM (32--33%). However, at larger concentrations, the inhibition by carbidopa was almost twice as strong (61 vs 36% at 250 μM and 80 vs 44% at 500 μM). Table 1.Inhibition of liver kynureninase activity *in vitro* by BSZ and carbidopaKynureninase activity (nmol of anthranilic acid formed/h per mg of protein)Inhibitor concentration (μM)BenserazideCarbidopa01.87 ± 0.111.87 ± 0.11101.45 ± 0.12\*1.55 ± 0.10251.34 ± 0.06\*1.41 ± 0.06\*1001.28 ± 0.07\*1.26 ± 0.04\*2501.20 ± 0.08\*0.73 ± 0.09\*5001.04 ± 0.11\*0.38 ± 0.03\*[^1]

Kynurenine aminotransferase activity was also determined simultaneously with that of kynureninase by measuring the increase in KA formation. In data to be reported elsewhere, both BSZ and carbidopa inhibited kynurenine aminotransferase activity, with the inhibition by carbidopa being stronger than that by BSZ at all concentrations tested.

Kynureninase activity was also determined after the acute administration of BSZ, carbidopa, Trp and combinations of Trp with either drug. The results in Fig. [6](#AGR135F6){ref-type="fig"}a show that Trp alone did not inhibit kynureninase activity. Trp administration (30 mg/kg intraperitoneally) has previously been reported ([@AGR135C42]) to enhance kynureninase activity by 15 and 21% at 2 and 3 h, respectively. As no such enhancement was observed in the present work at these time-intervals, a closer examination of a possible early increase was made. At 1.5 h after Trp administration, kynureninase activity (6.08 ± 0.49, expressed as in Fig. [5](#AGR135F5){ref-type="fig"}) was still not significantly different (*P *\> 0.1) from the control zero-time value (5.78 ± 0.27). However, a significant increase of 37% was observed at 0.5 h (7.91 ± 0.26; *P *= 0.0005). Fig. 6.Time-course of effects of acute administration of tryptophan, BSZ, carbidopa or a combination of tryptophan with BSZ or carbidopa on rat liver kynureninase activity. Experimental details are as described for the ALDH experiments in Fig. [2](#AGR135F2){ref-type="fig"}. Kynureninase activity was determined as described in the 'Materials and Methods' section. Values are means ± SEM (bars) for each group of five rats for tryptophan alone (**a**), BSZ with and without tryptophan (**b**) and carbidopa with and without tryptophan (**c**). For abbreviations, see Fig. [4](#AGR135F4){ref-type="fig"}.

As expected, both BSZ and carbidopa inhibited kynureninase activity. As shown in Fig. [6](#AGR135F6){ref-type="fig"}b, BSZ caused a significant inhibition (43%; *P *= 0.0003) only at 1 h, whereas carbidopa (Fig. [6](#AGR135F6){ref-type="fig"}c) caused a similar inhibition (41%; *P *= 0.0013) at 2 h. The inhibition by BSZ was not undermined by combined Trp administration (Fig. [6](#AGR135F6){ref-type="fig"}b). In fact, a constant level of inhibition (of 30--35%; *P *= 0.0196--0.0036) was sustained over the first 3 h, and that at 4 h (23%) was still significant (*P *= 0.0462). As BSZ was administered 30 min before Trp, the latter could be said to have prolonged the BSZ inhibition by 3.5 h. By contrast, the kynureninase inhibition by carbidopa was totally reversed by co-administration of Trp (Fig. [6](#AGR135F6){ref-type="fig"}c).

Kynureninase activity was also determined after chronic administration of Trp, BSZ or both for 7 days. In data not shown, kynureninase activity was decreased by BSZ by 22% and co-administration of Trp did not modify this decrease. In fact, Trp induced a further decrease. Trp alone exerted no effect on kynureninase activity. Under these chronic conditions, BSZ also inhibited kynurenine aminotransferase activity, by 61% and Trp, which exerted no significant effect when given alone, caused a further significant decrease when co-administered with BSZ (data not shown).

Hepatic kynurenine metabolites after the acute administration of tryptophan, carbidopa, BSZ or various combinations {#s3f}
-------------------------------------------------------------------------------------------------------------------

As stated above, the main effect of kynureninase inhibition (by BSZ and carbidopa) is the elevation of hepatic \[3-HK\]. However, because these two drugs also inhibit kynurenine aminotransferase activity, the potential increase in xanthurenic acid (due to 3-HK elevation) may be hampered by such latter inhibition. Although hepatic concentrations of Trp and six of its kynurenine metabolites were measured in the present work, only the data on \[3-HK\] are reported here, as details of other changes and their discussion fall outside the scope of this paper. As shown in Fig. [7](#AGR135F7){ref-type="fig"}, the 3-HK precursor Trp administered alone caused relatively large increases in liver \[3-HK\] at 3--4 h, with the 190% increase at 3 h being significant, compared with the zero-time control value (*P *= 0.016). The much smaller increases at 1 and 2 h were not significant. By contrast and as expected, both BSZ (Fig. [7](#AGR135F7){ref-type="fig"}a) and carbidopa (Fig. [7](#AGR135F7){ref-type="fig"}b) induced large increases in \[3-HK\] (*P *= 0.004--0.001), which were comparable at 1 and 2 h. Thereafter, the \[3-HK\] elevations by carbidopa remained close to the maximum increases, whereas those by BSZ showed a dramatic drop towards normal values. Fig. 7.Time-course of increases in hepatic 3-HK concentration after acute administration of tryptophan, BSZ, carbidopa or a combination of tryptophan with BSZ or carbidopa. 3-HK concentration was determined in livers of the same rats undergoing the time-course experiments with ALDH and kynureninase reported in Figs. [2](#AGR135F2){ref-type="fig"} and [6](#AGR135F6){ref-type="fig"} as described in the 'Materials and Methods' section. Values are means ± SEM (bars) for each group of five rats for the BSZ (**a**) and carbidopa (**b**) experiments. Abbreviations and comparisons are as in Figs. [2](#AGR135F2){ref-type="fig"}, [4](#AGR135F4){ref-type="fig"} and [6](#AGR135F6){ref-type="fig"}.

When BSZ administration was followed 0.5 h later by that of Trp, a dramatic elevation of \[3-HK\] was observed at 1 h after the Trp injection, with a 1069% increase over the baseline zero-time value (*P *= 0.008). This increase was a 152% higher than that induced by BSZ alone at this time-interval (*P *=  0.008). The \[3-HK\] elevation by the combined BSZ plus Trp treatment continued to be much higher than that by BSZ alone at the 2--4 h time points (*P *= 0.05--0.001). By contrast, when carbidopa was administered 0.5 h before Trp, there was no potentiation of the carbidopa-induced elevation of \[3-HK\] by Trp. In fact, none of the \[3-HK\] values observed with this combination differed significantly from those obtained with carbidopa alone at 1--3 h (*P *\> 0.1) and the value at 4 h was even 26% smaller (*P *= 0.034) after the combined treatment.

Animal body weights during repeated administration of tryptophan, BSZ or both {#s3g}
-----------------------------------------------------------------------------

In the aversion experiments reported in Fig. [4](#AGR135F4){ref-type="fig"}, rats gained weight during the first 3 days of the test. However, as was the case with disulfiram and kynurenine metabolites in the preceding paper ([@AGR135C5]), a wt loss of 6--7% occurred in all group rats on the morning of the fourth day, following the 18 h-water-deprivation period.

Changes in body wt of rats given single daily injections of saline, Trp, BSZ or a combination of Trp plus BSZ for 7 days in the chronic experiments were also recorded. Rats of all groups gained wt. On Day 7, the wt gain over the starting wt on Day 1 was 19, 21, 21 and 17%, respectively for the above four groups. No significant differences in body wt were observed after analysis of variance in within- or between-group comparisons (*P *\> 0.1).

Body weights of mice in the preference experiments were also recorded. All mice (*n* = 32) gained wt during the 16-day free choice period (from 19.44 ± 0.16 to 21.85 ± 0.21 g; *P *\< 0.001) (means ± SEM). Body weights remained stable during the 6-day drug administration period, with small rises of 1--3%. No significant differences within- or between-groups were observed (*P* \> 0.1). Both rats and mice appeared healthy and showed no adverse reactions or unusual behaviours.

DISCUSSION {#s4}
==========

Inhibition of ALDH activity by combined administration of tryptophan plus BSZ {#s4a}
-----------------------------------------------------------------------------

The present study was based on the assumption that Trp administered alone is metabolized along the kynurenine pathway so rapidly that sufficient levels of its ALDH-inhibitory metabolite 3-HK ([@AGR135C5]) may not be achieved or sustained to any significant extent, but that this could occur after metabolic blockade of the further degradation of 3-HK to 3-HAA by inhibition of kynureninase activity (Fig. [1](#AGR135F1){ref-type="fig"}). This assumption was borne out by the present findings that the combined administration of Trp plus the kynureninase inhibitor BSZ (but not Trp alone) caused a strong and sustained inhibition of the rat liver mitochondrial low K~m~ ALDH activity (Fig. [2](#AGR135F2){ref-type="fig"}a). This is almost certainly due to this combination inducing a remarkable and sustained elevation of hepatic \[3-HK\] (Fig. [7](#AGR135F7){ref-type="fig"}a) resulting from kynureninase inhibition by BSZ \[shown here under acute (Fig. [6](#AGR135F6){ref-type="fig"}b) and chronic (see the text) conditions as well as *in vitro* (Table [1](#AGR135TB1){ref-type="table"})\] superimposed on supply of 3-HK by its Trp precursor. As shown in Fig. [7](#AGR135F7){ref-type="fig"}, Trp alone increased liver \[3-HK\] significantly only at 3 h, but to a much lesser extent than that observed after kynureninase inhibition by BSZ. The latter drug alone did not influence the mitochondrial low K~m~ enzyme after acute (Fig. [2](#AGR135F2){ref-type="fig"}a) or chronic (see the text) administration. As carbidopa also inhibits kynureninase activity ([@AGR135C9]; [@AGR135C7]), it was also studied in the present work. Surprisingly, carbidopa did not inhibit ALDH activity after acute administration either alone or in combination with Trp (Fig. [2](#AGR135F2){ref-type="fig"}b), although it inhibited kynureninase activity both *in vitro* (Table [1](#AGR135TB1){ref-type="table"}) and after acute administration (Fig. [6](#AGR135F6){ref-type="fig"}c) and induced increases in liver \[3-HK\] (Fig. [7](#AGR135F7){ref-type="fig"}b) comparable with those by BSZ alone (Fig. [7](#AGR135F7){ref-type="fig"}a). Furthermore, Trp did not potentiate the increase in liver \[3-HK\] caused by carbidopa (Fig. [7](#AGR135F7){ref-type="fig"}b) and this may explain the failure of the combined Trp plus carbidopa treatment to inhibit ALDH activity. As ALDH activity was not inhibited by Trp, BSZ, carbidopa or the latter combined with Trp, it may be suggested that the \[3-HK\] elevation under these four conditions (up to ∼50 μM) (Fig. [7](#AGR135F7){ref-type="fig"}) was not sufficient to cause inhibition of the enzyme when assayed *in vitro*. In the ALDH assay *in vitro*, the liver is diluted a 100-fold and the resulting \[3-HK\] of up to 0.5 μM under the above conditions may have been too small to cause inhibition, whereas a 3-HK concentration of \>1 μM in the combined Trp plus BSZ group was more effective. ALDH activity has previously been shown to be inhibited by chronic administration of BSZ ([@AGR135C28]) and acute administration of carbidopa ([@AGR135C29]). However, this author used the cytosolic, rather than the mitochondrial low K~m~, enzyme in both studies.

The kynureninase inhibition by BSZ was prolonged by Trp after acute administration (Fig. [6](#AGR135F6){ref-type="fig"}b) and potentiated after chronic administration (see the text). A possible explanation of these effects of Trp is the greater elevation of \[3-HK\] after the combined treatment, compared with that after BSZ alone. Evidence from kinetic studies with purified recombinant human kynureninase demonstrating a sigmoidal concentration-activity profile suggests that 3-HK may inhibit kynureninase activity at higher concentrations ([@AGR135C46]). By contrast, Trp prevented the kynureninase inhibition by carbidopa (Fig. [6](#AGR135F6){ref-type="fig"}c). It is well known ([@AGR135C45]) that many hydrazine compounds inactivate pyridoxal 5′-phosphate-dependent enzymes by forming inactive hydrazides with this cofactor. As both BSZ and carbidopa possess a hydrazine group, the above differential effect of Trp on kynureninase inhibition by BSZ and carbidopa is intriguing and requires further investigation. Trp itself stimulated kynureninase activity transiently at 0.5 h, by 37% (Fig. [6](#AGR135F6){ref-type="fig"}a). A15--21% stimulation has previously been observed by [@AGR135C42] at 2--3 h after a 30 mg/kg body wt dose of Trp. The latter authors did not provide a possible explanation of this stimulation in normal rats (as opposed to an inhibition they reported in vitamin B~6~-deficient animals due to depletion of the pyridoxal 5′-phosphate cofactor through the flux of Trp down the kynurenine pathway). It is possible that Trp or a metabolite thereof may interact with carbidopa to undermine its effect on this enzyme, but further work is required to elucidate the nature of such a potential interaction.

Inhibition of ALDH activity *in vivo* by combined administration of tryptophan plus BSZ {#s4b}
---------------------------------------------------------------------------------------

The above ALDH inhibition by combined administration of Trp plus BSZ was also observed *in vivo*, as the results in Fig. [3](#AGR135F3){ref-type="fig"} show. This combined treatment induced a large increase in blood acetaldehyde concentration following acute ethanol administration (Fig. [3](#AGR135F3){ref-type="fig"}a), which mirrored the \[3-HK\] elevation (Fig. [7](#AGR135F7){ref-type="fig"}a). Whereas BSZ alone exerted no effect on blood acetaldehyde, Trp showed a trend towards elevation, though the increases were not significant. The data in Fig. [3](#AGR135F3){ref-type="fig"}b show Trp to cause small, though not significant, decreases in blood-ethanol concentration at 2 and 3 h. It is possible that significant decreases could occur at subsequent time intervals after Trp administration, possibly due to acceleration of ethanol oxidation through provision of NAD^+^. As this redox cofactor is a terminal metabolite of the kynurenine pathway (Fig. [1](#AGR135F1){ref-type="fig"}), its concentration could be expected to show a greater rise at later time-intervals.

Induction of aversion to alcohol by combined administration of tryptophan plus BSZ {#s4c}
----------------------------------------------------------------------------------

The combined treatment of rats with Trp plus BSZ induced a decrease in alcohol consumption in the aversion model of [@AGR135C17] (Fig. [4](#AGR135F4){ref-type="fig"}a), consistent with the ALDH inhibition observed after their combined administration and in the *in vivo* assay, whereas neither compound caused aversion when administered separately. The effect of Trp on alcohol consumption is a controversial one, with an increase ([@AGR135C35]) and a decrease ([@AGR135C40]) having both been reported following Trp administration in the rats' diet. BSZ has also previously been shown not to inhibit alcohol consumption by cats ([@AGR135C6]) or rats ([@AGR135C30]; [@AGR135C32]) after systemic (intraperitoneal or subcutaneous) administration, but, when given intracerebroventricularly to rats whose alcohol consumption was augmented by prior cyanamide treatment, it decreased it ([@AGR135C32]). While this experimental paradigm may have scientific merit for the purposes of this particular study, it is clearly an artificial one not applicable to standard human pharmacotherapeutic practice. By contrast, carbidopa has been reported to inhibit alcohol consumption ([@AGR135C30]). Our finding (Fig. [4](#AGR135F4){ref-type="fig"}b) that this kynureninase inhibitor induced aversion to alcohol by itself supports this previous finding. An unexpected finding in the present work was the ability of Trp to block the alcohol aversive effect of carbidopa (Fig. [4](#AGR135F4){ref-type="fig"}b). The mechanism of the carbidopa-induced aversion to alcohol cannot be explained at present. [@AGR135C30] suggested ALDH inhibition as a possible mechanism, though as stated above, this inhibition was demonstrated ([@AGR135C29]) using the cytosolic enzyme. An effect of carbidopa on blood acetaldehyde after ethanol administration, however, cannot be ruled out. However, in the absence of such evidence and in view of the failure of carbidopa to inhibit the mitochondrial low K~m~ enzyme (Fig. [2](#AGR135F2){ref-type="fig"}b), other mechanisms must be considered, including central ones. As Trp also prevented the kynureninase inhibition by carbidopa (Fig. [6](#AGR135F6){ref-type="fig"}c), it is possible that this latter effect may be related to the above effects on alcohol consumption. However, a more likely, or additional, explanation for the modulation by Trp of the carbidopa effect on alcohol consumption may be related to carbidopa metabolism. Unlike BSZ, which is metabolised and distributed almost entirely outside the brain ([@AGR135C37]), carbidopa is metabolised in rats first by deamination to α-methyldopa, which can readily cross the blood-brain barrier to form α-methyl dopamine, and this is then followed by β-hydroxylation to α-methyl noradrenaline ([@AGR135C38]). These latter authors suggested that the main function of α-methyl dopamine formed centrally through carbidopa metabolism is via α-methyl noradrenaline, which is a potent α~2~ adrenoceptor agonist, which may influence alcohol consumption. Thus, one α~2~-agonist, lofexidine, has been reported ([@AGR135C23]) to attenuate stress-induced reinstatement of alcohol-seeking behaviour and to also decrease alcohol self-administration, whereas the opposite effects were induced by the α~2~ antagonist yohimbine. Another α~2~ agonist, FLA-57, also reduces alcohol consumption ([@AGR135C39]; [@AGR135C14]). The brain entry of α-methyldopa formed peripherally from carbidopa could be inhibited through competition by Trp, which shares the same carrier mechanism responsible for the transport of neutral (aromatic and branched-chain) amino acids and also *L*-dopa itself across the blood-brain barrier ([@AGR135C36]). For example, administration of *L*-dopa (200 mg/kg) to rats decreases brain \[Trp\] and \[5-HT\] ([@AGR135C1]), and it is believed that the incidence of depressive symptoms in patients with Parkinson\'s disease is due to serotonin depletion secondarily to exogenous *L*-dopa inhibiting Trp uptake by the brain, with Trp administration successfully alleviating these symptoms ([@AGR135C31]). A larger *L*-dopa dose (500 mg/kg), however, elevates brain \[Trp\] by increasing plasma \[free Trp\] secondarily to stimulating the lipolytic release of non-esterified fatty acids ([@AGR135C13]). It is therefore possible that aversion to alcohol induced by carbidopa may involve a central mechanism and that Trp blocks it by preventing the cerebral uptake of the carbidopa metabolite α-methyldopa. Further work will be required to assess this possibility.

The combined tryptophan-BSZ strategy for alcoholism treatment {#s4d}
-------------------------------------------------------------

The above results have provided proofs of mechanism (ALDH inhibition after administration and *in vivo*) and principle (induction of aversion to alcohol) by the combined administration of Trp and the kynureninase inhibitor BSZ. A European patent (to AA-BB) is expected shortly for use of this combination in alcoholism treatment by aversion and proof of concept studies demonstrating the ability of this combination to induce aversion to alcohol in human subjects will be an important step in the further development of this intellectual property. This proposed combination is not limited to its aversive property, but can address several other aspects of the alcohol dependence mechanism in addition to alcohol consumption. Thus: (1) the use of Trp can elevate brain serotonin levels to counteract two important determinants of relapse after detoxification, namely anxiety and depression. (2) A third determinant of relapse is the hyperexcitability of the acute alcohol-withdrawal syndrome, believed to be due to NMDA receptor activation ([@AGR135C18]; [@AGR135C24]) and suggested to be mediated by the endogenous NMDA receptor agonist quinolinic acid ([@AGR135C34]). Minimizing the peripheral formation of this Trp metabolite by kynureninase inhibition (Fig. [1](#AGR135F1){ref-type="fig"}) can only contribute to its decreased entry into the brain ([@AGR135C19]). (3) Furthermore, cerebral levels of the NMDA receptor antagonist KA are likely to be increased through increased entry of kynurenine into the brain with Trp loading. Thus, plasma and brain kynurenine concentrations have been shown ([@AGR135C16]) to be increased at 1h after intraperitoneal administration of a 50 mg/kg body wt dose of Trp by 110 and 57% respectively. In the present work, serum Trp and kynurenine concentrations after chronic administration of Trp in the above single daily dose for 7 days were increased by 121 and 131% respectively and joint BSZ administration influenced the kynurenine elevation only moderately (data not shown). Although Trp competes with kynurenine for cerebral uptake (see [@AGR135C33] and references cited therein), the above proportionate increases are unlikely to cause an imbalance in entry of either compound into the brain. Although BSZ inhibits liver kynurenine aminotransferase activity (data not shown), a similar effect in the brain is unlikely as BSZ does not cross the blood-brain barrier. Accordingly, the combined Trp plus BSZ treatment is likely to lead to elevation of cerebral KA concentration, leading to NMDA receptor antagonism. The proposed combination could therefore afford dual neuronal protection. (4) As regards reward mechanisms, although the above negative reinforcing properties (anxiety, depression and hyperexcitability) appear to play a more important role in alcohol dependence than the positive rewarding effects, it is also possible that provision of serotonin from Trp in the proposed therapy may modulate the alcohol reward effect. Although dopamine plays a central role in the brain reward mechanisms, other neurotransmitters are also capable of modulating this role, including serotonin, GABA (γ-aminobutyric acid), glutamate and endogenous opioids ([@AGR135C21]) and the importance of the interactions between these systems has been emphasized in relation to alcohol research and treatment ([@AGR135C22]). It is therefore possible that Trp-derived serotonin could also modulate alcohol reward through interacting with dopaminergic and opioidergic, and possibly other, systems. We therefore believe that the Trp-BSZ combination represents a new and unique multifaceted approach to combination therapy of alcohol dependence.

There should be little safety issues with the combined use of Trp plus BSZ. In the present work (see the text), test rats and mice gained weight at a normal rate as control animals and showed no side effects. Weight gain and food intake were also reported to be normal after repeated subcutaneous BSZ administration ([@AGR135C32]). Both Trp and BSZ are currently licensed for use  in resistant depression and Parkinson\'s disease, respectively (the latter in combination with *L*-dopa). A clinical trial for treatment of schizophrenia with Trp plus BSZ for 6 weeks did not report undue adverse events different from those experienced by a control schizophrenic group treated with chlorpromazine ([@AGR135C12]). The combined use of Trp plus BSZ is also the subject of a US patent ([@AGR135C44]) for the treatment of chronic pain, in which the inventor successfully used this combination in humans with no reported adverse events. BSZ alone has also been used in a trial in schizophrenia ([@AGR135C11]) with no reported adverse events.
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[^1]: Enzyme activity was determined as described in the 'Materials and Methods' section. Values are means ± SEM for each group of liver preparations from four rats. The asterisk denotes a significant difference from the corresponding control value (*P *= 0.0450--0.0000).
